Fimasartan is a novel selective AT1 receptor blockers, in a variety of types of hypertension showed a rapid and effective antihypertensive effect, very safe and has good tolerance, superior to other similar drugs.
For new vasopressin V2 receptor antagonist, urine excretion function, can improve the blood sodium ion concentration, produce beneficial hemodynamic changes. Its oral is convenient, no drug rapid desensitization, such as high natremia obvious adverse affects. By Japan Otsuka company research and development, on July 26, 2006 was approved in Japan.
No comments:
Post a Comment